Does Plavix cause hair loss? Plavix (clopidogrel) is an antiplatelet medicine widely prescribed across the UK to reduce the risk of blood clots, heart attacks, and strokes. Whilst hair loss is not among its common side effects, it is classified as a rare adverse reaction in the MHRA-approved Summary of Product Characteristics. This article explores how frequently clopidogrel-related hair loss occurs, why it may happen, what steps to take if you notice thinning, and how your healthcare team can help you manage this concern safely without compromising your cardiovascular protection.

Can Plavix (Clopidogrel) Cause Hair Loss?

Clopidogrel can cause hair loss, but it is classified as a rare adverse reaction in the MHRA-approved SmPC, with no firmly established causal link and many concurrent factors that may contribute.

Experiencing these side effects? Our pharmacists can help you navigate them →

Plavix is the brand name for clopidogrel, an antiplatelet medicine commonly prescribed in the UK to reduce the risk of blood clots, heart attacks, and strokes. It works by irreversibly inhibiting the platelet P2Y12 ADP receptor, preventing platelets from clumping together and forming dangerous clots. Clopidogrel is a prodrug, meaning it must be converted to its active form in the body. It is widely used following a heart attack, stroke, or the placement of a coronary stent, and features prominently in UK secondary cardiovascular prevention.

When it comes to hair loss, the picture is nuanced. Hair loss (medically termed alopecia) is not listed as a common side effect of clopidogrel in the Summary of Product Characteristics (SmPC) approved by the Medicines and Healthcare products Regulatory Agency (MHRA). According to the current UK SmPC for clopidogrel, alopecia is classified as a rare adverse reaction. It has been reported through post-marketing surveillance — that is, after the medicine entered widespread use — even though it was not consistently identified during clinical trials.

It is important to note that there is no firmly established causal link between clopidogrel and significant hair loss. Many patients who report hair thinning whilst taking clopidogrel may be experiencing hair loss due to other concurrent factors — including the underlying cardiovascular condition itself, stress, nutritional changes, or other medicines taken alongside clopidogrel. Nevertheless, patient-reported experiences should always be taken seriously and discussed with a healthcare professional.

For authoritative information on clopidogrel, patients and clinicians can refer to the NHS Medicines A–Z page for clopidogrel, the MHRA/EMC SmPC, and the EMA's European Public Assessment Report (EPAR) for Plavix.

How Common Is Hair Loss as a Side Effect?

Hair loss occurs in fewer than 1 in 1,000 patients taking clopidogrel, placing it in the rare category; most patients will not experience any hair thinning.

Not sure if this is normal? Chat with one of our pharmacists →

According to the current MHRA-approved SmPC for clopidogrel, alopecia is classified as a rare adverse reaction, occurring in fewer than 1 in 1,000 patients. This places it well outside the category of common side effects, which include bleeding, bruising, and gastrointestinal upset. Some other medicines — including certain chemotherapy agents and some anticoagulants — have been reported in their respective SmPCs and published literature to be associated with hair thinning, though direct comparisons should be interpreted cautiously as reporting rates vary.

Post-marketing pharmacovigilance — the ongoing monitoring of medicines once they are in widespread use — has captured a small number of spontaneous reports of hair loss in patients taking clopidogrel. These reports are collected through the MHRA's Yellow Card scheme, which allows both patients and healthcare professionals to flag suspected adverse drug reactions. A Yellow Card report does not confirm causation; it signals that the event occurred whilst the patient was taking the medicine. If you suspect clopidogrel or any other medicine is causing a side effect, you are encouraged to report it via the MHRA Yellow Card website (yellowcard.mhra.gov.uk) or the Yellow Card app.

In clinical practice, the following points help contextualise the risk:

• Most patients taking clopidogrel will not experience any hair loss.

• Hair thinning, if it does occur, is typically diffuse (spread across the scalp) rather than patchy, consistent with a pattern known as telogen effluvium.

• The condition often improves after discontinuation of the medicine, though this is not guaranteed and must only be considered under medical supervision.

• Older age, female sex, and nutritional deficiencies may independently increase susceptibility to hair thinning, making it harder to attribute the cause solely to the medication.

Why Some Medicines Affect Hair Growth

Medicines can disrupt the hair growth cycle, pushing follicles into the telogen (shedding) phase — a process called telogen effluvium — which typically begins two to four months after the triggering event.

To understand why any medicine might contribute to hair loss, it helps to know a little about the hair growth cycle. Hair follicles pass through three phases: anagen (active growth), catagen (transition), and telogen (resting and shedding). Disruption to this cycle — whether through illness, nutritional deficiency, hormonal change, or certain drugs — can push a larger proportion of hairs into the telogen phase simultaneously, resulting in noticeable shedding. This is known as telogen effluvium, and is described in detail in British Association of Dermatologists (BAD) patient information.

Drug-induced alopecia can occur through two main mechanisms. The first, anagen effluvium, involves direct damage to actively dividing hair follicle cells — this is the mechanism seen with chemotherapy. The second, telogen effluvium, is more gradual and typically begins two to four months after the triggering event, which is why patients may not immediately connect their hair loss to a medicine they started several months earlier.

In the case of clopidogrel, the precise mechanism by which it might contribute to hair loss is not established. The cardiovascular events for which clopidogrel is prescribed — such as a heart attack or stroke — are themselves significant physiological stressors that can independently trigger telogen effluvium, making it genuinely difficult to separate the effect of the illness from the effect of the medicine. This is an important consideration when evaluating any reported association.

What to Do If You Notice Hair Thinning on Clopidogrel

Do not stop clopidogrel without medical advice; instead, arrange a GP appointment to investigate other causes, review your full medication list, and consider appropriate blood tests.

If you are taking clopidogrel and notice increased hair shedding or thinning, the most important first step is not to stop taking your medication without medical advice. Clopidogrel is prescribed for serious cardiovascular conditions, and abruptly discontinuing it — particularly if you have a coronary stent — can significantly increase the risk of a life-threatening blood clot. This is a critical patient safety point.

Instead, arrange an appointment with your GP to discuss your concerns. Your doctor will likely:

• Take a thorough history to identify other potential causes of hair loss, including thyroid dysfunction, iron deficiency, or hormonal changes.

• Consider blood tests based on your clinical history and examination findings — commonly a full blood count, ferritin, and thyroid function tests. Additional tests (such as B12, folate, or coeliac screen) may be requested if clinically indicated. Routine testing for vitamin D or zinc is not recommended unless there is a specific clinical reason.

• Review your full medication list, as other medicines you may be taking alongside clopidogrel — such as statins, beta-blockers, or antihypertensives — can also be associated with hair thinning.

• Assess the pattern and severity of hair loss to determine whether referral to NHS dermatology is appropriate.

Keep a simple diary noting when you first noticed the hair loss, how much hair you are losing, and any other new symptoms. This information will be invaluable to your GP.

Seek prompt medical attention if you notice any of the following, as these may indicate a condition requiring urgent assessment:

• Rapid or extensive hair loss

• Patchy loss with scalp redness, scaling, pain, or scarring

• Loss of eyebrows or eyelashes

• Associated systemic symptoms such as significant fatigue, unexplained weight change, or skin changes

These features may point to an underlying medical condition rather than a drug side effect, and your GP can refer you to NHS dermatology if needed. Further information on investigating hair loss is available via NICE Clinical Knowledge Summaries (CKS) and the NHS hair loss patient page.

Alternatives and Managing Side Effects Safely

Any change to antiplatelet therapy must be made by a specialist; alternatives such as ticagrelor or prasugrel exist, but hair loss has been reported with these agents too and switching does not guarantee resolution.

If investigations confirm that clopidogrel is the most likely cause of your hair loss, your cardiologist or GP may consider whether an alternative antiplatelet agent is appropriate for your specific clinical situation. It is essential that any change to antiplatelet therapy is made by a specialist, particularly if you have had a recent cardiac event or have a coronary stent in situ, as the risks of switching must be carefully weighed against the benefits. NICE guidance on antiplatelet treatment and secondary prevention provides the framework for these decisions in the UK.

Alternative antiplatelet medicines used in the UK include:

• Aspirin — often used in combination with clopidogrel (dual antiplatelet therapy) or alone for long-term secondary prevention.

• Ticagrelor — another P2Y12 inhibitor, sometimes used as an alternative to clopidogrel following acute coronary syndrome.

• Prasugrel — used in specific patient groups, particularly those undergoing percutaneous coronary intervention.

Each of these alternatives carries its own side effect profile, and hair loss has been reported with other antiplatelet agents, albeit rarely, according to their respective SmPCs. There is no guarantee that switching will resolve hair thinning, particularly if other contributing factors are present.

Regarding general measures to support hair health: do not start iron, zinc, or other supplements without first discussing this with your GP or pharmacist, and only if a deficiency has been confirmed through testing. In particular, the MHRA has issued a Drug Safety Update warning that biotin (vitamin B7) supplementation can interfere with a range of laboratory tests, potentially causing misleading results. Taking biotin without medical advice is therefore not recommended.

A referral to NHS dermatology may be appropriate if hair loss is significant or distressing. If you choose to see a trichologist privately, be aware that trichologists are not medically regulated in the UK and cannot prescribe medicines or diagnose medical conditions; any concerns about an underlying medical cause should be assessed by your GP or a dermatologist.

Above all, do not adjust your cardiovascular medication independently. The protection clopidogrel provides against serious cardiovascular events is well established, and your healthcare team can help you find the safest path forward. If you believe clopidogrel is causing a side effect, please also consider reporting this via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Frequently Asked Questions